Results 31 to 40 of about 38,336 (234)
Induction of peripheral tolerance in ongoing autoimmune inflammation requires interleukin 27 signaling in dendritic cells [PDF]
, 2017 Peripheral tolerance to autoantigens is induced via suppression of self-reactive lymphocytes, stimulation of tolerogenic dendritic cells (DCs) and regulatory T (Treg) cells.
Mari, Elisabeth R. +3 more
core +2 more sources
Expression of CD39 on FoxP3+ T regulatory cells correlates with progression of HBV infection [PDF]
, 2012 BACKGROUND: Although it is known that regulatory T cells (Tregs) can suppress the function of effector T cells, and may contribute to impaired immune response, the precise role of Tregs during the course of hepatitis B virus (HBV) infection remains to be
Bing Ni +4 more
core +2 more sources
Implications of CD39 in immune-related diseases
International Immunopharmacology, 2020 Extracellular adenosine triphosphate (eATP) mediates pro-inflammatory responses by recruiting and activating inflammatory cells. CD39 can hydrolyze eATP into adenosine monophosphate (AMP), while CD73 can convert AMP into the immunosuppressive nucleoside adenosine (ADO).
Jianrui, Zeng +3 more
openaire +2 more sources
Frontiers in Oncology, 2020 The ectonucleoside triphosphate diphosphohydrolase (CD39)/5′ ectonuclotidase (CD73)-dependent purinergic pathway emerges as promising cancer target. Yet, except for own previous work revealing a pathogenic role of CD73 and adenosine in radiation-induced ...
Alina V. Meyer +7 more
doaj +1 more source
Nonsense-mediated decay mechanism is a possible modifying factor of clinical outcome in nonsense cd39 beta thalassemia genotype [PDF]
, 2012 Nonsense-mediated mRNA decay (NMD) is a surveillance system to prevent the synthesis of non-functional proteins. In β-thalassemia, NMD may have a role in clinical outcome.
ATTANASIO, Massimo +11 more
core +1 more source
Frontiers in Genetics, 2021 BackgroundCD39 is one of the functional surface markers for T regulatory cells, the prognostic role and immune-related effects of CD39 in luminal breast cancer (BC) patients has not been evaluated yet.
Xiaojian Ni +13 more
doaj +1 more source
Science-Business eXchange, 2009 American and German researchers have reported that enhancing CD39 activity in the gut could help treat inflammatory bowel disease. The researchers are now developing a soluble form of CD39 that they hope could become an infusible therapeutic to treat colitis and Crohn's disease.
openaire +1 more source
CD39 Modulates Endothelial Cell Activation and Apoptosis [PDF]
Molecular Medicine, 2000 CD39 is the dominant vascular nucleoside triphosphate diphosphohydrolase (NTPDase) that exerts major effects on platelet reactivity by the regulated hydrolysis of extracellular adenine nucleotides. The effects of NTPDases on endothelial cell (EC) activation and apoptosis remain unexplored.Recombinant replication-deficient adenoviruses were constructed ...
C, Goepfert +5 more
openaire +2 more sources
A humanized monoclonal antibody targeting CD39 with novel mechanism for cancer treatment
Medicine in Drug Discovery, 2021 ATP-adenosine signal axis plays an import role in tumor immune regulation. ATP released by tumor cells can promote antitumor immunity, and adenosine can suppress the immune response.
Zheng Wei +5 more
doaj +1 more source
Redox control of multidrug resistance and Its possible modulation by antioxidants [PDF]
, 2016 Clinical efficacy of anticancer chemotherapies is dramatically hampered by multidrug resistance (MDR) dependent on inherited traits, acquired defence against toxins, and adaptive mechanisms mounting in tumours.
Cort, A. +4 more
core +3 more sources